Nautilus Biotechnology shares surge 10.4% intraday following Voyager platform launch and strategic collaborations.

Nautilus Biotechnology (NAUT) surged 10.4% intraday following a series of positive announcements, including the launch of its Voyager single-molecule proteomics platform, a collaboration with Weill Cornell Medicine-Qatar, and the appointment of a new vice president of sales. Recent news highlighted early access programs for its Tau proteoforms assay, strategic partnerships in Parkinson’s disease research, and participation in key industry conferences, signaling strong product development and market expansion momentum. These developments reinforced investor confidence in the company’s innovative capabilities and growth prospects, aligning with the intraday price surge. Unrelated news about maritime labor policies, watch designs, and Middle East energy conflicts did not impact the stock’s movement.